This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 350.00% and 7.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) in Focus: Stock Moves 9.8% Higher
by Zacks Equity Research
CareDx (CDNA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
CareDx Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
CareDx has been struggling lately, but the selling pressure may be coming to an end soon.
Best Sector of 2018 and its Hit ETFs & Stocks
by Sweta Killa
Healthcare was the best-performing sector of 2018 and we have highlighted top-performing ETFs and stocks from this sector.
CareDx (CDNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 50.00% and 14.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
Teladoc (TDOC) Hits 52-Week High, Will the Rally Continue?
by Zacks Equity Research
Strong second-quarter earnings performance and favorable guidance pulled up the stock of Teladoc (TDOC).
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 20.00% and 16.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Steer Clear of LifePoint (LPNT) Stock
by Zacks Equity Research
LifePoint (LPNT) continues to suffer due to a challenging volume environment and weak revenues.
The Zacks Analyst Blog Highlights: Aetna, CareDx, PRA Health Sciences and Diplomat Pharmacy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aetna, CareDx, PRA Health Sciences and Diplomat Pharmacy
4 Attractive Stocks to Buy in an Evolving Healthcare Space
by Zacks Equity Research
The evolving healthcare industry presents an attractive buying opportunity for investors.
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioLife Solutions, SeaSpine Holdings, Apollo Endosurgery and CareDx
4 Top-Ranked Growth Stocks in MedTech Under $20
by Zacks Equity Research
In the wake of the turbulent political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable picks.
Teladoc Rides on Growing Demand for Telehealth Services
by Zacks Equity Research
Rising demand for telehealth services is likely to create long-term growth opportunities for Teladoc's (TDOC).
Low Waste Revenues to Hurt Stericycle's (SRCL) Q3 Earnings?
by Zacks Equity Research
Stericycle (SRCL) is likely to record lower revenues from Regulated Waste and Compliance Services segment due to aggressive pricing by competitors to gain market share, resulting in lower earnings for the quarter.
Will Tinder & PMC Growth Aid Match Group (MTCH) Q3 Earnings?
by Zacks Equity Research
Match Group's (MTCH) third-quarter 2017 earnings results to benefit from steady market traction of apps like Tinder, which are driving higher PMC (paid-member count).
PAREXEL's Acquisition by Pamplona Approved by Shareholders
by Zacks Equity Research
The long-awaited PAREXEL (PRXL) acquisition by Pamplona Capital Management finally receives shareholders' approval. Moreover, the company plans to go private post-acquisition.
Land on 5 Winning Stocks with the Ignored Rising P/E Trick
by Zacks Equity Research
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
What's in the Cards for Box, Inc (BOX) in Q1 Earnings?
by Zacks Equity Research
Box, Inc. (BOX) is set to report first-quarter fiscal 2018 results on May 31. Last quarter, the company delivered a positive earnings surprise of 6.67%.
Intuit (INTU) to Report Q3 Earnings: Will it Disappoint?
by Zacks Equity Research
Intuit Inc. (INTU) is set to report third-quarter 2017 results on May 23.
Can FactSet Research (FDS) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
FactSet Research Systems Inc. (FDS) is set to report second-quarter fiscal 2017 results on Mar 28.